Bristol Myers (BMY) was upgraded to a Zacks Rank #2 (Buy), signaling improved optimism around its earnings outlook. The note suggests upside momentum for the stock in the near term, though no specific financial metrics were provided.
Bristol Myers (BMY) was upgraded to a Zacks Rank #2 (Buy), signaling improved optimism around its earnings outlook. The note suggests upside momentum for the stock in the near term, though no specific financial metrics were provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
